Premera Blue Cross has posted a stakeholder review notice (feedback due March 5, 2026) listing multiple MDC 09 Dermatology & Plastic Surgery policies under consideration, including scar/wound management, breast reconstruction, and body-contouring procedures. Policies called out for review include fractional CO2 laser for hypertrophic scars/keloids, recombinant/autologous platelet-derived growth factors for wound healing, adipose-derived stem cells in autologous fat grafting to the breast, panniculectomy and excision of redundant skin, and reconstructive breast surgery/implant management. The document is an intake notification only and does not contain revised coverage language, criteria, or coding changes; it identifies topics open for feedback. This review is part of a broader multi-specialty policy cycle that includes other non-dermatology items also open for comment.
March 5, 2026 Revision: Policies Listed for Stakeholder Feedback
This document itemizes policies for review with a request to submit feedback by March 5, 2026. It highlights a set of discrete policy numbers and titles that are being considered, including multiple items relevant to dermatology and plastic surgery under MDC 09: Dermatology & Plastic Surgery (Skin/Breast). The listing explicitly includes 2.01.107 Fractional Carbon Dioxide (CO2) Laser Ablation Treatment of Hypertrophic Scars or Keloids for Functional Improvement, 7.01.153 Adipose-Derived Stem Cells in Autologous Fat Grafting to the Breast, 7.01.523 Panniculectomy and Excision of Redundant Skin, and 7.01.533 Reconstructive Breast Surgery/Management of Breast Implants among others.
The revision notice does not provide specific amended language for any single policy; rather, it functions as an intake/notification that these listed policies are the subject of review. Therefore, the principal "change" presented is the identification of these policy titles and numbers as items open for stakeholder feedback with the specified deadline.
Scope: Scar Management and Wound Healing Policies Identified
The list includes several dermatology- and plastic surgery-related policies under MDC 09: Dermatology & Plastic Surgery (Skin/Breast). Notable entries are 2.01.107 Fractional Carbon Dioxide (CO2) Laser Ablation Treatment of Hypertrophic Scars or Keloids for Functional Improvement and 2.01.543 Recombinant and Autologous Platelet-Derived Growth Factors for Wound Healing and Other Non-Orthopedic Conditions, which are directly relevant to management of scars and wound healing.
These items indicate a focused review of interventions used in treatment of hypertrophic scars and keloids and adjunctive biologic therapies for wound healing. No substantive policy language or coverage determinations are provided in the notice itself; only the policy identifiers and titles are presented for review.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.